Teenagers and young adults living with perinatally acquired HIV (PaHIV) have a higher risk of developing malignancies and a higher all-cause mortality rate than their non-HIV-infected peers, according to a study from the UK.
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Use of triple antiretroviral therapy (ART) during pregnancy and breastfeeding did not affect the cognitive development and function of the offspring compared with those whose mothers were not exposed to ART, reveals the IMPAACT PROMISE-BF study presented at the IAC 2018.
The combination of dolutegravir + lamivudine appeared noninferior to dolutegravir + tenofovir/emtricitabine in reducing viral load in treatment-naïve patients with HIV-1 infection, according to the phase III GEMINI-1 and GEMINI-2* trials presented at AIDS 2018.
Simplification from combination antiretroviral therapy (cART) to dolutegravir monotherapy as maintenance treatment was noninferior to continuing therapy with cART, at least in patients who initiated cART during primary HIV infection and had achieved suppressed viral load for ≥48 weeks, suggests a study presented at IAC 2018.
The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.
Ageing, nondiabetic, HIV-positive individuals may have a greater tendency to develop insulin resistance than HIV-negative individuals, although their body mass index (BMI) and body fat levels were lower than that of HIV-negative individuals, a study from Thailand found.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.